Implantable Defibrillators and Cardiac Amyloidosis: Infiltrating the Knowledge Gap.

Cardiac Amyloidosis (CA) is a rare disease, with a prevalence of 18-55 cases per 100,000 person-years [1]. However, our understanding of this disease has improved in recent years, which has allowed for better recognition and screening processes. The role of implantable cardioverter defibrillators (ICDs) has not yet been thoroughly defined in this population. This article is protected by copyright. All rights reserved.